PCI Biotech Holding ASA (LTS:0JGL) Notes Receivable: kr0.00 Mil (As of Jun. 2025)


What is PCI Biotech Holding ASA Notes Receivable?

PCI Biotech Holding ASA LTS:0JGL Notes Receivable is kr0.00 Mil as of Jun. 2025. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's Notes Receivable for the quarter that ended in Jun. 2025 was kr0.00 Mil.

PCI Biotech Holding ASA Notes Receivable Related Terms

PCI Biotech Holding ASA Notes Receivable Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Notes Receivable Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCI Biotech Holding ASA Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Notes Receivable of kr0.00 Mil as of Jun. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Notes Receivable too high?
PCI Biotech Holding ASA's current Notes Receivable is kr0.00 Mil.
How does PCI Biotech Holding ASA's Notes Receivable compare to VRTX and REGN?
PCI Biotech Holding ASA's Notes Receivable of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Notes Receivable of kr0.00 Mil. The current Notes Receivable is kr0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Notes Receivable is kr0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.